Michael Fried is a hepatologist who has performed translational and clinical studies related to viral hepatitis. He has served as the principal investigator or co-investigator on numerous phase I through phase III clinical trials that have contributed greatly to defining the treatment of chronic viral hepatitis and to characterizing direct-acting antiviral agents, which are the newest generation of therapeutics for hepatitis C. He served as Chair or co-Chair of three NIH-sponsored clinical research networks in viral hepatitis. He is currently the co-Chair of the NIH NIDDK Hepatitis B Research Network, which is performing clinical and laboratory studies of patients in different phases of hepatitis B infection. More recently, he has served as co-PI with Dr. David Nelson at University of Florida, of an international multicenter longitudinal, observational study of patients being treated for HCV at academic and community medical centers in order to understand the true real world safety and effectiveness of new treatment regimens for hepatitis C (HCV-TARGET). He has been awarded two PCORI grants (Fried, co-PI) to evaluate patient reported outcomes with HCV therapy, using the HCV-TARGET infrastructure. He received the Food and Drug Administration’s Award for Regulatory Science Excellence for HCV-TARGET.